Schlom J - Search Results

1

The role of soluble CD40L in immunosuppression.

Schlom J, Jochems C, Gulley JL, Huang J. Schlom J, et al. Oncoimmunology. 2013 Jan 1;2(1):e22546. doi: 10.4161/onci.22546. Oncoimmunology. 2013. PMID: 23483661 Free PMC article.

2

Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.

Zhu M, Terasawa H, Gulley J, Panicali D, Arlen P, Schlom J, Tsang KY. Zhu M, et al. Among authors: schlom j. Cancer Res. 2001 May 1;61(9):3725-34. Cancer Res. 2001. PMID: 11325845

3

The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.

von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM. von Mehren M, et al. Among authors: schlom j. Clin Cancer Res. 2001 May;7(5):1181-91. Clin Cancer Res. 2001. PMID: 11350882 Clinical Trial.

4

The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.

Tsang KY, Zhu M, Even J, Gulley J, Arlen P, Schlom J. Tsang KY, et al. Among authors: schlom j. Cancer Res. 2001 Oct 15;61(20):7568-76. Cancer Res. 2001. PMID: 11606396

5

Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.

Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J. Terasawa H, et al. Among authors: schlom j. Clin Cancer Res. 2002 Jan;8(1):41-53. Clin Cancer Res. 2002. PMID: 11801539

6

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J. Gulley J, et al. Among authors: schlom j. Prostate. 2002 Oct 1;53(2):109-17. doi: 10.1002/pros.10130. Prostate. 2002. PMID: 12242725 Clinical Trial.

7

A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1.

Arlen PM, Gulley JL, Palena C, Marshall J, Schlom J, Tsang KY. Arlen PM, et al. Among authors: schlom j. J Immunol Methods. 2003 Aug;279(1-2):183-92. doi: 10.1016/s0022-1759(03)00185-6. J Immunol Methods. 2003. PMID: 12969559

8

Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.

Arlen PM, Gulley JL, Tsang KY, Schlom J. Arlen PM, et al. Among authors: schlom j. Expert Rev Vaccines. 2003 Aug;2(4):483-93. doi: 10.1586/14760584.2.4.483. Expert Rev Vaccines. 2003. PMID: 14711334 Review.

9

A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.

Tsang KY, Palena C, Gulley J, Arlen P, Schlom J. Tsang KY, et al. Among authors: schlom j. Clin Cancer Res. 2004 Mar 15;10(6):2139-49. doi: 10.1158/1078-0432.ccr-1011-03. Clin Cancer Res. 2004. PMID: 15041735

10

Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation.

Schlom J, Palena C, Greiner JW, Tsang KY, Grosenbach DW, Sabzevari H, Gulley JL, Arlen PM, Kass E, Hodge JW. Schlom J, et al. Dev Biol (Basel). 2004;116:27-47. Dev Biol (Basel). 2004. PMID: 15603182 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

724 results

Search Page